# Biote Reports First Quarter 2026 Financial Results
Canonical URL: https://biopharmsignal.com/news/BTMD/biote-reports-first-quarter-2026-financial-results
Ticker: BTMD
Company: biote Corp
Source: biote Corp
Published: 2026-05-06 20:05 EST
Original Source URL: https://ir.biote.com
## Summary

Sales team expansion on track and nearing targeted level Return to procedure growth expected in second half of 2026 First Quarter 2026 Financial Highlights Revenue of $44.9 million Gross profit margin of 68.9% Net income of $2.7 million and diluted earnings per share attributable to biote Corp.

## Article Body
Sales team expansion on track and nearing targeted level Return to procedure growth expected in second half of 2026 First Quarter 2026 Financial Highlights Revenue of $44.9 million Gross profit margin of 68.9% Net income of $2.7 million and diluted earnings per share attributable to biote Corp.
## Recent Company News
- 2026-06-01 12:00 EST — [Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer](https://biopharmsignal.com/news/BTMD/biote-appoints-komal-bajaj-md-ms-as-chief-medical-officer) — Source: biote Corp
- 2026-05-28 13:00 EST — [Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO](https://biopharmsignal.com/news/BTMD/biote-names-bob-peterson-current-chief-financial-and-chief-business-officer-as-interim-ceo) — Source: biote Corp
- 2026-05-06 20:05 EST — [Biote Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/BTMD/biote-reports-first-quarter-2026-financial-results) — Source: biote Corp
- 2026-04-22 20:05 EST — [Biote Schedules First Quarter 2026 Financial Results Release and Conference Call](https://biopharmsignal.com/news/BTMD/biote-schedules-first-quarter-2026-financial-results-release-and-conference-call) — Source: biote
- 2026-03-11 20:05 EST — [Biote Reports Fourth Quarter and Full Year 2025 Financial Results](https://biopharmsignal.com/news/BTMD/biote-reports-fourth-quarter-and-full-year-2025-financial-results) — Source: biote Corp
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)